Scholarlink

Background <p>Breast cancer (BC) prognosis is influenced by hormones, of which progesterone receptor (PR) status is controversial for BC prognosis, possibly related to clinical characteristics.</p> Objective <p>This study was to determine the impact of PR status on BC prognosis and explore the differences across patient subgroups.</p> Methods <p>PubMed, Cochrane Library, Embase, and Web of Science were searched for relevant studies until July 2024. NOS (Newcastle–Ottawa Scale) was leveraged for quality appraisal. Meta-analysis was performed using STATA15.1.</p> Results <p>Thirty-five studies were included, involving 89,164 patients. PR-negative status was associated with worse overall survival compared to PR-positive status (HR 1.70, 95%CI 1.42 to 2.04; <i>p</i> &lt; 0.001). Similar results were unveiled for disease-free survival (HR 1.62, 95%CI 1.23 to 2.14, <i>p</i> &lt; 0.001), breast-cancer-specific survival (HR 2.45, 95% CI 1.85 to 3.23, <i>p</i> &lt; 0.001), and recurrence-free survival (HR 1.47, 95% CI 1.21 to 1.79, <i>p</i> &lt; 0.001). Subgroup analyses unveiled that conclusions were influenced by region, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, menopausal status, and metastatic status.</p> Conclusion <p>PR loss is associated with worse outcomes in BC, which is influenced by clinical characteristics. Especially in patients with ER + HER2- tumors, PR status may serve as an additional predictive marker.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of progesterone receptor status with breast cancer prognosis: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月2日

查看全文
  • Yiming Hou,
  • Jianrong Li,
  • Qiong Zhang,
  • Yingyi Fan

摘要

Background

Breast cancer (BC) prognosis is influenced by hormones, of which progesterone receptor (PR) status is controversial for BC prognosis, possibly related to clinical characteristics.

Objective

This study was to determine the impact of PR status on BC prognosis and explore the differences across patient subgroups.

Methods

PubMed, Cochrane Library, Embase, and Web of Science were searched for relevant studies until July 2024. NOS (Newcastle–Ottawa Scale) was leveraged for quality appraisal. Meta-analysis was performed using STATA15.1.

Results

Thirty-five studies were included, involving 89,164 patients. PR-negative status was associated with worse overall survival compared to PR-positive status (HR 1.70, 95%CI 1.42 to 2.04; p < 0.001). Similar results were unveiled for disease-free survival (HR 1.62, 95%CI 1.23 to 2.14, p < 0.001), breast-cancer-specific survival (HR 2.45, 95% CI 1.85 to 3.23, p < 0.001), and recurrence-free survival (HR 1.47, 95% CI 1.21 to 1.79, p < 0.001). Subgroup analyses unveiled that conclusions were influenced by region, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, menopausal status, and metastatic status.

Conclusion

PR loss is associated with worse outcomes in BC, which is influenced by clinical characteristics. Especially in patients with ER + HER2- tumors, PR status may serve as an additional predictive marker.